Innovative Cancer Therapies
for a Healthier Tomorrow

Fulgent Pharma is a clinical stage pharmaceutical company focused on developing and commercializing innovative cancer therapeutics. Our pipeline includes both improved chemotherapy drugs through nanoencapsulation and innovative new drug candidates, all of which are targeted at treating a broad range of cancers, including breast, lung, ovarian, colon, and pancreatic cancer.

The company's lead asset is FID-007, a nanoencapsulated paclitaxel with improved drug efficacy and decreased toxicity, which is currently being tested in clinical trials.


Current Drug Development & Drug Delivery Programs

Nanoencapsulation of Poorly Soluble Drugs

Nanoencapsulation of poorly soluble drugs with non-toxic, non-immunogenic, and biocompatible polymers has successfully enhanced drug delivery, safety, and effectiveness. Fulgent Pharma combines its patented nanoencapsulation technology with both established and early-discovery anti-cancer drugs to create new therapies with lower toxicity, targeted delivery, and enhanced tumor reduction.


Benefits

  • Better low-dose efficacy, tumor penetration, and safety profiles
  • No need for premedication (steroids and/or antihistamines)
  • An ideal platform for combo drugs (e.g., nano-paclitaxel, gemcitabine)

Targeted Therapeutics

Targeted therapies for primary human myelodysplastic syndrome (MDS) progenitors and hematopoietic stem cells (HSC).


Immuno-Oncology

Small-molecule based checkpoint inhibitors. Enhancing nano-biotherapeutics with next generation sequencing.